Updates are available Correction dated 2025-03-10

Article History

Accepted: 21 December 2024

First Online: 13 January 2025

Change Date: 10 March 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11523-025-01138-4

Declarations

:

: All named authors meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published. This article was prepared according to the International Society for Medical Publication Professionals’ Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3.

: This study was funded by Gilead Sciences.

: José Ángel García-Saenz has received consultant and/or speaker honoraria from Asofarma, AstraZeneca, Celgene, Daichii Sankyo, Eisai, Eli Lilly, Exact Sciences, Gilead, Jazz Pharmaceuticals, Menarini, MSD, Nolver (Adium), Novartis, Pfizer, Roche, Seagen, and Tecnofarma; research funding from AstraZeneca; and travel support from AstraZeneca, Daiichi Sankyo, and Gilead. Álvaro Rodríguez-Lescure has received consulting or advisory role fees from AstraZeneca, Daiichi-Sankyo, Eisai, Gilead, Eli Lilly, MSD, Novartis, Pfizer, Roche, and Seagen; research funding from Astellas, AstraZeneca, Bristol Myers Squibb, Eli Lilly, GEICAM, GILEAD, MSD, Novartis, Pfizer, Radius, Roche, and Zymeworks; and travel support from Novartis, Pfizer, and Roche. Josefina Cruz has received consultant and/or speaker honoraria from AstraZeneca, Daichii Sankyo, Deciphera, Eisai, Eli Lilly, Gilead, GlaxoSmithKline, Novartis, Pharmamar, Pierre Fabre, Roche, Seagen, and Pfizer, and travel support from AstraZeneca, Daiichi Sankyo, Gilead, Novartis, Pharmamar, and Roche. Joan Albanell has received consultant and/or speaker honoraria from Amgen, AstraZeneca, Daichii Sankyo, Eli Lilly, Gilead, Menarini, MSD, Pfizer, and Roche; research funding/grant support from Amgen, Daichii Sankyo, Eli Lilly, MSD, Pfizer, Novartis, and Roche; and travel support from Amgen, AstraZeneca, Daiichi Sankyo, Eli Lilly, MSD, Novartis, Pfizer, and Roche; and holds patents on LCOR and EGFR ECD (licensed), and stock options in Inbiomotion. Emilio Alba has received consultant and/or speaker honoraria from Exact Science, Gilead, Novartis, and Pfizer. Antonio Llombart has received consultant and/or speaker honoraria from AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, and Roche; research funding from Agendia, AstraZeneca, Eli Lilly, Gilead, MSD, Novartis, Pfizer, and Roche; and travel support from AstraZeneca, MSD, Pfizer, and Roche.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: JAGS, ARL, JC, JA, EA, and AL contributed equally to the conception, design, and writing of the manuscript. All approved the submitted version.